Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00594698 · ClinicalTrials.gov registry record · Phase 2
Familiarization and Safety Study of PB127 Ultrasound Contrast Agent
A Phase 2 study of Coronary Artery Disease, sponsored by Point Biomedical.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 20
- Study locations
NCT00594698 is a Phase 2 study of Coronary Artery Disease that has completed, run by Point Biomedical. The registered enrollment target is 150 participants, below the 1,286-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT00594698, a Phase 2 study of Coronary Artery Disease, has completed, sponsored by Point Biomedical.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate preparation and administration of PB127, echocardiographic images obtained during PB127 administration, and evaluate the safety of PB127.
Conditions Studied
Interventions
- DRUG PB127 for injectable suspension
Study Locations (20)
California
- Long Beach VA Medical Center Cardiology Division - Long Beach
- University of California San Diego Division of Cardiology - San Diego
- San Francisco VA Medical Center NCIRE - San Francisco
- University of California San Francisco - San Francisco
- Stanford University Medical Center - Stanford
Arizona
- Michael Morgan, MD - Phoenix
- Heartcare, P.C. - Scottsdale
- Mayo Clinic Scottsdale - Scottsdale
Missouri
- Cardiovascular Consultants - Kansas City
- St. Louis University Medical Center - St Louis
- Washington University School of Medicine - St Louis
Maine
- Androscoggin Cardiovascular Associates - Auburn
- Maine Cardiology Associates - South Portland
District of Columbia
- Washington Hospital Center Cardiovascular Research Institute - Washington D.C.
Illinois
- University of Chicago Medical Center - Chicago
Indiana
- Krannert Institute of Cardiology - Indianapolis
Kansas
- The Center for Cardiovascular Studies Kramer and Crouse Cardiology - Shawnee Mission
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2002-02 |
| Est. Completion | 2003-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00594698
The ClinicalTrials.gov registry entry for NCT00594698 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,286-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (88% lower). The listed sponsor is Point Biomedical, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Coronary Artery Disease appearing as the primary indexed condition, and to 1 intervention - of which PB127 for injectable suspension is the first listed.
NCT00594698 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Arizona, Missouri.
Frequently Asked Questions
What is clinical trial NCT00594698 about?
NCT00594698 is a clinical study titled "Familiarization and Safety Study of PB127 Ultrasound Contrast Agent". The purpose of this study is to evaluate preparation and administration of PB127, echocardiographic images obtained during PB127 administration, and evaluate the safety of PB127.
What is the current status of trial NCT00594698?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2002-02. Estimated completion is 2003-09.
What conditions does trial NCT00594698 study?
This clinical trial studies the following conditions: Coronary Artery Disease.
What interventions are being tested in trial NCT00594698?
The interventions under investigation include: PB127 for injectable suspension (DRUG).
Who is sponsoring clinical trial NCT00594698?
This trial is sponsored by Point Biomedical, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00594698 being conducted?
This trial has 20 study locations across Arizona, California, District of Columbia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Investigational Trial to Evaluate XC001 Delivered Via an Cardiac Catheter in Subjects With Chronic Angina.
RECRUITING · Phase 2
-
Prevent Cardiac Surgery Associated AKI Trial
RECRUITING · Phase 2
-
MARS - Monitored Atherosclerosis Regression Study
COMPLETED · Phase 2
-
High Ticagrelor Loading Dose in STEMI
COMPLETED · Phase 2
-
TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent
COMPLETED · Phase 2
-
Custodiol-HTK (Histidine-tryptophan-ketoglutarate) Solution as a Cardioplegic Agent
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.